Asian stocks rose, with the regional index heading for a five-month high, as Senate leaders said they��e optimistic they will forge a deal to reopen the U.S. government and avoid a breach of the debt limit this week.
James Hardie Industries SE, a maker of building materials that gets about 70 percent of sales from the U.S., increased 1.5 percent in Sydney. Mazda Motor Corp. (7261) jumped 3.3 percent in Tokyo after Macquarie Group Ltd. and BNP Paribas raised ratings on the carmaker. Hankook Tire Co., South Korea�� No. 1 tiremaker, advance 1.8 percent after announcing plans to build its first factory in the U.S.
The MSCI Asia Pacific Index gained 0.5 percent to 141.57 as of 11:07 a.m. in Tokyo, with almost three shares rising for each that fell. Senate Majority Leader Harry Reid said ��remendous progress��had been made, though ��e are not there yet.�� Leaders are working on an deal to suspend the debt ceiling through Feb. 7 and fund the government through Jan. 15, a person familiar with the talks said, speaking on the condition of anonymity.
Best New Companies To Invest In Right Now: FireEye Inc (FEYE)
FireEye, Inc., incorporated on February 18, 2004, invented a purpose-built, virtual machine-based security platform that provides real-time protection to enterprises and governments worldwide against the next generation of cyber attacks. Its technology approach represents a paradigm shift from how information technology (IT) security has been conducted since the earliest days of the information technology industry. The FireEye platform provides real-time, dynamic threat protection without the use of signatures to protect an organization across the primary threat vectors, including Web, email, and files and across the different stages of an attack life cycle. The core of its purpose-built, virtual machine-based security platform is its virtual execution (MVX), engine, which identifies and protects against known and unknown threats that existing signature-based technologies are unable to detect. The new generation of cyber attacks on organizations, including large and small enterprises and governments worldwide, is characterized by an unprecedented escalation in the complexity and scale of advanced malware created by criminal organizations and nation-states. In January 2014, FireEye, Inc. announced that it had acquired Mandiant.
The Company provides a comprehensive platform that employs a virtualized execution engine and a cloud-based threat intelligence network that uniquely protects organizations from next-generation threats at all stages of the attack lifecycle and across all primary threat vectors, including Web, email and file systems. Its platform is delivered through a family of software-based appliances and includes its DTI cloud subscription as well as support and maintenance services. Its technology platform, built on its MVX engine, is able to identify and protect against known and unknown threats without relying on existing signature-based technologies employed by legacy IT security vendors and best-of-breed point solution vendors. FireEye has over 1,000 customers across more t! han 40 countries, including over one-third of the Fortune 100.
Advisors' Opinion:- [By Maureen Farrell]
Shares of ad buying platform Rocket Fuel (FUEL) nearly doubled on their first day of trading while cybersecurity firm FireEye's (FEYE) shares more than doubled.
- [By WWW.DAILYFINANCE.COM] BOSTON -- The U.S. Department of Homeland Security advised computer users to consider using alternatives to Microsoft's Internet Explorer browser until the company fixes a security flaw that hackers have used to launch attacks. The bug is the first high-profile security flaw to emerge since Microsoft (MSFT) stopped providing security updates for Windows XP earlier this month. That means PCs running the 13-year old operating system could remain unprotected against hackers seeking to exploit the newly uncovered flaw, even after Microsoft figures out how to defend against it. The United States Computer Emergency Readiness Team, a part of Homeland Security known as US-CERT, said in an advisory released Monday that the vulnerability in versions 6 to 11 of Internet Explorer could lead to "the complete compromise" of an affected system. "We are currently unaware of a practical solution to this problem," Carnegie Mellon's Software Engineering Institute warned in a separate advisory, that US-CERT linked to in its warning. Versions 6 to 11 of Internet Explorer dominate desktop browsing, accounting for 55 percent of the PC browser market, according to tech research firm NetMarketShare. Google Inc's Chrome and Mozilla's Firefox account for the majority of the rest of the traffic. News of the vulnerability surfaced over the weekend as Microsoft said its programmers were rushing to fix the problem as quickly as possible. Cybersecurity software maker FireEye Inc warned that a sophisticated group of hackers have been exploiting the bug in a campaign dubbed "Operation Clandestine Fox." FireEye (FEYE), whose Mandiant division helps companies respond to cyber attacks, declined to name specific victims or identify the group of hackers, saying that an investigation into the matter is still active. "It's a campaign of targeted attacks seemingly against U.S.-based firms, currently tied to defense and financial sectors," FireEye spokesman Vitor De Souza said Sunday. "It
Hot Diversified Bank Stocks To Watch Right Now: Carbo Ceramics Inc. (CRR)
CARBO Ceramics Inc. manufactures and supplies resin-coated ceramic and resin-coated sand proppants primarily used in the hydraulic fracturing of natural gas and oil wells in the United States and internationally. The company offers proppants, including CARBOHSP and CARBOPROP designed for use in deep gas wells; CARBOLITE used in medium depth oil and gas wells; CARBOECONOPROP; CARBOHYDROPROP used to enhance performance in slickwater fracture treatments; CARBOBOND LITE for oil and natural gas wells that are subject to the risk of proppant flow-back; and CARBOBOND RCS, a conductivity proppant. It also provides fracture simulation software, as well as offers fracture design, engineering, and consulting services to oil and natural gas companies. In addition, the company provides a range of technologies for spill prevention, containment, countermeasures, and geotechnical monitoring, as well as offers monitoring systems and services for bridges, buildings, tunnels, dams, slopes, e mbankments, volcanoes, landslides, mines, and construction projects primarily for customers in auto racing teams, surveyors, experimental physicists, radio astronomers, and naval architects markets. It principally sells its products and services to operators of oil and natural gas wells, and oilfield service companies. The company was founded in 1987 and is headquartered in Houston, Texas.
Advisors' Opinion:- [By Alex Planes]
Investors love stocks that consistently beat the Street without getting ahead of their fundamentals and risking a meltdown. The best stocks offer sustainable market-beating gains, with robust and improving financial metrics that support strong price growth. Does CARBO Ceramics (NYSE: CRR ) fit the bill? Let's take a look at what its recent results tell us about its potential for future gains.
- [By Geoff Gannon]
A German blogger just posted about this site. It is a list of the most shorted stocks in the USA...
I was surprised that ITT Educational (ESI), Carbo Ceramics (CRR), and Boston Beer (SAM) are on this list... - [By Seth Jayson]
Basic guidelines
In this series, I examine inventory using a simple rule of thumb: Inventory increases ought to roughly parallel revenue increases. If inventory bloats more quickly than sales grow, this might be a sign that expected sales haven't materialized. Is the current inventory situation at CARBO Ceramics (NYSE: CRR ) out of line? To figure that out, start by comparing the company's inventory growth to sales growth. How is CARBO Ceramics doing by this quick checkup? At first glance, not so great. Trailing-12-month revenue decreased 1.3%, and inventory increased 7.5%. Comparing the latest quarter to the prior-year quarter, the story looks potentially problematic. Revenue shrank 9.5%, and inventory increased 7.5%. Over the sequential quarterly period, the trend looks worrisome. Revenue dropped 3.9%, and inventory grew 4.8%. - [By Aaron Levitt]
At its core, CARBO Ceramics (CRR) manufactures synthetic proppants used in oil and gas drilling. The takeaway for E&P firms willing to cough up the extra bucks for ��rtificial sand��is that they are able to squeeze out more natural gas and shale oil from wells using CRR�� products — about 20% more. That extra production, especially given the high price for oil, can mean the difference between whether a project is profitable or not.
Hot Diversified Bank Stocks To Watch Right Now: Inovio Pharmaceuticals Inc (INO)
Inovio Pharmaceuticals, Inc., incorporated on June 29, 1983, is engaged in the development of a new generation of vaccines, called synthetic vaccines, focused on cancers and infectious diseases. The Company's SynCon technology enables the design of universal vaccines capable of providing cross-protection against existing or changing strains of pathogens, such as influenza and human immunodeficiency virus (HIV). The Company's electroporation delivery technology uses brief, controlled electrical pulses to increase cellular uptake of the vaccine. Its clinical programs include cervical dysplasia (therapeutic), avian influenza (preventive), prostate cancer (therapeutic), leukemia (therapeutic), hepatitis C virus (HCV) and HIV vaccines. It is advancing preclinical research and clinical development for a universal seasonal/pandemic influenza vaccine, as well as preclinical work for other products, including malaria and prostate cancer vaccines. Its partners and collaborators include University of Pennsylvania, Drexel University, National Microbiology Laboratory of the Public Health Agency of Canada, Program for Appropriate Technology in Health/Malaria Vaccine Initiative (PATH/MVI), National Institute of Allergy and Infectious Diseases (NIAID), Merck, ChronTech, University of Southampton, United States Military HIV Research Program (USMHRP), the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) and HIV Vaccines Trial Network (HVTN). As of December 31, 2011 it owned 16.1% interest in VGX Int��.
Inovio�� Solution
The Company�� synthetic vaccine platform consists of its SynCon vaccine design process and electroporation delivery technology. It has developed a preclinical and clinical stage pipeline of vaccines. The Company�� synthetic vaccines are designed to prevent a disease (prophylactic vaccines) or treat an existing disease (therapeutic vaccines). Its synthetic vaccine consists of a deoxyribonucleic acid (DNA) plasmid encoding a selected antigen! (s), which is introduced into cells of humans or animals with the purpose of evoking an immune response to the encoded antigen. The Company�� synthetic vaccines are designed to generate specific antibody and/or T-cell responses.
The Company�� SynCon technology provides processes that employ bioinformatics, which combine extensive genetic data and sophisticated algorithms. Its design process uses the genetic make-up of a common antigen(s) from multiple strains of a virus within a viral sub-type or taxonomic group (family) of pathogens, such as HIV, hepatitis C virus (HCV), human papillomavirus (HPV), influenza and other diseases to synthetically create a new antigen for the desired pathogen target that does not exist in nature. Its synthetic vaccine candidates are being delivered into cells of the body using its electroporation (EP) DNA delivery technology.
Cancer Synthetic Vaccines
The Company has two broad types of cancer vaccines: preventive (or prophylactic) vaccines, which are intended to prevent cancer from developing in healthy people, and treatment (or therapeutic) vaccines, which are intended to treat an existing cancer by strengthening the body�� natural defenses against the cancer. Two types of cancer preventive vaccines are available in the United States. The United States Food and Drug Administration (the FDA) has approved two vaccines, Gardasil and Cervarix that protect against infection by the two types of HPV-types 16 and 18-that cause approximately 70% of all cases of cervical cancer worldwide. In addition, Gardasil protects against infection by two additional HPV types, 6 and 11, which are responsible for about 90% of all cases of genital warts in males and females but do not cause cervical cancer.
Cervarix manufactured by GlaxoSmithKline, is composed of virus-like particles (VLPs) made with proteins from HPV types 16 and 18. Cervarix is approved for use in females��ages 10 to 25 for the prevention of cervical cancer caused by! HPV type! s 16 and 18. Gardasil manufactured by Merck, is approved for use in females for the prevention of cervical cancer, and some vulvar and vaginal cancers, caused by HPV types 16 and 18 and for use in males and females for the prevention of genital warts caused by HPV types 6 and 11. The vaccine is approved for these uses in females and males ages 9 to 26. The FDA has also approved a cancer preventive vaccine that protects against hepatitis B virus (HBV) infection.
Inovio�� VGX-3100 is designed to raise immune responses against the E6 and E7 genes of HPV types 16 and 18 that are present in both pre-cancerous and cancerous cells transformed by these HPV types. E6 and E7 are oncogenes that play an integral role in transforming HPV-infected cells into cancerous cells. In March 2011, it initiated a randomized, double-blind Phase II study of VGX-3100 delivered using the CELLECTRA intramuscular electroporation device in women with HPV Type 16 or 18 and diagnosed with, but not yet treated for, cervical intraepithelial neoplasia (CIN) 2/3. The study is designed to enroll 148 subjects. In January 2011, it announced the publication of a scientific paper in the journal Human Vaccines detailing potent immune responses in a preclinical study of its SynCon vaccine for prostate cancer targeting two antigens, prostate specific antigen (PSA) and prostate specific membrane antigen (PSMA).
In January 2011, the Company announced the regulatory approval of a Phase II clinical trial (WIN Trial) to treat leukemia utilizing its new ELGEN 1000 automated vaccine delivery device. The single dose level, Phase II study, called WT1 immunity via DNA fusion gene vaccination in haematological malignancies by intramuscular injection followed by intramuscular electroporation. Cancer Vaccines encodes for hTERT, an antigen related to non-small cell lung, breast and prostate cancers. The vaccine is delivered using its electroporation delivery technology.
Infectious Disease Synthetic Vaccines
In Marc! h 2011, the Company announced the initiation of a follow-on open label, single dose Phase II clinical study in collaboration with ChronTech of the ChronVac-C HCV DNA vaccine delivered using its electroporation technology in treatment naive HCV infected individuals. Its HIV vaccines consist of candidates for HIV prevention, as well as therapy or treatment. PENNVAX-B is designed to target HIV clade B (most commonly found in the United States, North America, Australia and the European Union (EU). PENNVAX-G is designed to target HIV clades A, C and D, which are more commonly found in Asia, Africa, Russia and South America. This Phase I clinical study of PENNVAX-B (HVTN-080) vaccinated 48 healthy, HIV-negative volunteers to assess safety and levels of immune responses generated by Inovio�� PENNVAX-B vaccine delivered with its CELLECTRA electroporation device. PENNVAX-B is a SynCon vaccine that targets HIV gag, pol, and env proteins.The Company�� VGX-3400X targets H5N1. The vaccine consists of three distinct DNA plasmids coded for a consensus hemagglutinin (HA) antigen derived from different H5N1 virus strains; a consensus neuraminidase (NA) antigen derived from different N1 sequences; and a consensus nucleoprotein (NP) fused to a small portion of the m2 protein (m2E) based on a broader cross-section of influenza viruses in addition to H5N1 and H1N1. Conventional vaccines are strain-specific and have limited ability to protect against genetic shifts in the influenza strains they target. They are therefore modified annually in anticipation of the next flu season�� new strain(s). It is focused on developing DNA-based influenza vaccines able to provide broad protection against known as well as newly emerging, unknown seasonal and pandemic influenza strains.
Animal Health/Veterinary
VGX Animal Health, Inc. (VGX AH), a majority-owned subsidiary, has licensed LifeTide, a plasmid-based growth hormone releasing hormone (GHRH) technology for swine. LifeTide is one of onl! y four DN! A-based treatments approved for use in animals and is the only DNA-based agent delivered using electroporation that has been granted marketing approval (Australia). VGX AH is also developing a GHRH-based treatment for cancer and anemia in dogs and cats. It is developing a synthetic vaccine for foot-and-mouth disease (FMD) administered by its vaccine delivery technology. The FMD virus is one of the most infectious diseases affecting farm animals, including cattle, swine, sheep and goats, and is a serious threat to global food safety.
The Company competes with Crucell N.V, Sanofi-Aventis, Novartis, Inc., GlaxoSmithKline plc, Merck, Pfizer, AstraZeneca, Inc., Novartis, Inc., MedImmune and CSL.
Advisors' Opinion:- [By George Budwell]
Inovio Pharmaceuticals (NYSEMKT: INO ) develops DNA-based vaccines and delivers them using a proprietary electroporation technique. Shares of Inovio have been a roller coaster all year long, and have certainly been the playground of day traders. Last week, Inovio shares lost more than 10% of their value on heavy volume, suggesting the stock may continue to experience downward pressure. This rapid move downward is surprising because the company recently signed a licensing deal with Roche (NASDAQOTH: RHHBY ) to commercialize Inovio's multi-antigen DNA immunotherapies for prostate cancer and hepatitis B. As part of the deal, Inovio received $10 million upfront, and milestone payments could go as high as $412 million.
- [By Sean Williams]
No fairytale ending
Fairytale endings work great in the movies, but you rarely see them come to fruition in the real world. Small-cap biopharmaceutical Inovio Pharmaceuticals (NYSEMKT: INO ) has seen shares nearly triple since April on the heels of multiple intriguing studies, but will the glass slipper fit over the long term? - [By Sean Williams]
On the clinical data front, Alnylam Pharmaceuticals (NASDAQ: ALNY ) and Inovio Pharmaceuticals (NYSEMKT: INO ) both put investors in their happy place.
Hot Diversified Bank Stocks To Watch Right Now: Navios Maritime Holdings Inc. (NM)
Navios Maritime Holdings Inc. operates as a seaborne shipping and logistics company. It focuses on the transportation and transshipment of dry bulk commodities, including iron ore, coal, fertilizers, and grains. The company controls a fleet of 31 owned vessels and 26 chartered-in vessels totaling 5.8 million dwt. Its owned fleet comprises 14 Ultra Handymax, 11 Capesize, 1 Handysize, and 3 Panamax vessels, as well as 2 Panamax vessels under construction; and chartered-in vessels consists of 8 Capesize, 11 Panamax, 1 Handysize, and 6 Ultra Handymax vessels under long-term time charters. The company also engages in port terminal, river barge, and coastal cabotage operations; and charters its vessels under medium to long-term charters to trading houses, producers, and government-owned entities. In addition, it engages in operating ports and transfer station terminals; and handles vessels, barges, and push boats, as well as operates upriver transport facilities in the Hidrovia region. Further, the company engages in the transportation and handling of liquid cargoes through the ownership, operation, and trading of tanker vessels. It has operations primarily in North America, Europe, Asia, and South America. The company is headquartered in Piraeus, Greece.
Advisors' Opinion:- [By Nickey Friedman]
Navios Maritime Holdings (NYSE: NM ) has two operating segments: shipping and logistics. Analysts have already begun to raise their profit estimates for 2014, currently at $0.11 EPS up from $0.01 a week ago. Expect that number to continue to rise dramatically. Navios pays a $0.06 per share quarterly dividend and trades around 40% below its book value. It used to trade as high as $17 back in 2007.
Hot Diversified Bank Stocks To Watch Right Now: Imperial Oil Limited(IMO)
Imperial Oil Limited engages in the exploration, production, and sale of crude oil and natural gas in Canada. The company operates through three segments: Upstream, Downstream, and Chemical. The Upstream segment engages in the exploration and production of conventional crude oil, natural gas, synthetic oil, and bitumen primarily in the Western Provinces, the Canada Lands, and the Atlantic Offshore. Its primary conventional oil producing asset includes the Norman Wells oil field in the Northwest Territories. The Downstream segment engages in the transportation and refining of crude oil, as well as blending, distribution, and marketing of refined products. It owns and operates crude oil, and natural gas liquids and products pipelines in Alberta, Manitoba, and Ontario. The Chemical segment engages in the manufacture and marketing of various petrochemicals, including ethylene, benzene, aromatic and aliphatic solvents, plasticizer intermediates, and polyethylene resin. As of De cember 31, 2010, Imperial Oil Limited had 1,204 million oil-equivalent barrels of proved undeveloped reserves; maintained a nation-wide distribution system, including 24 primary terminals, to handle bulk and packaged petroleum products moving from refineries to market by pipeline, tanker, rail, and road transport; and sold petroleum products through 1,850 Esso retail service stations, of which approximately 510 were company owned or leased. The company was founded in 1880 and is headquartered in Calgary, Canada. Imperial Oil Limited operates as a subsidiary of Exxon Mobil Corporation.
Advisors' Opinion:- [By Aaron Levitt]
Ten of Exxon�� major projects are expected to begin pumping energy throughout this year. These include expansions of Imperial Oil�� (IMO) oil sands production in Canada, new deepwater wells in the Gulf of Mexico as well as finally seeing production from its partnership in Russia. XOM �will start producing oil from the largest offshore oil and gas platform in that nation within a few months. These projects will add about 300,000 barrels per oil equivalent per day to Exxon�� production.
- [By Stephan Dube]
Cold Lake's most notable producers:
Husky Energy (HUSK.PK), see article here.Pengrowth Energy Corporation (PGH), see article here.Southern Pacific Resource (STPJF.PK), see article here.Canadian Natural Resources (CNQ), see article here.Devon Energy (DVN), see article here.Imperial Oil (IMO), see article here.Baytex, see article here.Bonavista Energy (BNPUF.PK), see article here.Athabasca's most notable producers:
- [By Caiman Valores]
But as highlighted earlier Whitecap's Canadian light sweet crude is not as heavily discounted as Canadian heavy oil or bitumen. This does not leave it exposed to the same price risks and volatility as those companies that have a significant portion of their production made up by Canadian heavy oil and Bitumen, such as Husky Energy (HUSKF.PK), Suncor (SU), Imperial Oil (IMO) and Canadian Natural Resources (CNQ).
No comments:
Post a Comment